China NMPA Product Recall - Albumin Assay Kit (Bromocresol Purple Method)

Roche Diagnostics Products (Shanghai) Co., Ltd. initiated a voluntary Level II recall for specific batches of its Albumin Assay Kit (Bromoxycresol Purple Method), as publicly reported on March 20, 2019. This measure was prompted by the discovery of potential calibration or quality control failures and deviations in results associated with these diagnostic kits. Such issues are critical, as accurate albumin assays are vital for various medical diagnoses and patient management. The recall operates under the regulatory framework established by the National Medical Products Administration (NMPA) and the Shanghai Food and Drug Administration, which oversees medical device registration and safety. The company acknowledged these discrepancies, confirming that detailed information on affected product models, specifications, and batch numbers is provided in a Medical Device Recall Event Report Form. This recall highlights the manufacturer's responsibility to ensure the reliability and precision of their products, adhering to stringent quality standards to safeguard public health. The NMPA ensures transparency in such regulatory actions, facilitating access to crucial recall information for healthcare providers and the public.